184 related articles for article (PubMed ID: 23870055)
1. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.
Anforth R; Blumetti TC; Clements A; Kefford R; Long GV; Fernandez-Peñas P
Br J Dermatol; 2013 Dec; 169(6):1310-3. PubMed ID: 23870055
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
Chon SY; Sambrano BL; Geddes ER
J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
Anforth R; Tembe V; Blumetti T; Fernandez-Peñas P
Pigment Cell Melanoma Res; 2012 Sep; 25(5):569-72. PubMed ID: 22726224
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
7. The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
Li H; Pedersen L; Nørgaard M; Ulrichsen SP; Thygesen SK; Nelson JJ
BMC Cancer; 2016 May; 16():295. PubMed ID: 27141983
[TBL] [Abstract][Full Text] [Related]
8. Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib.
Anforth R; Blumetti TC; Mohd Affandi A; Fernandez-Penas P
J Clin Oncol; 2012 Jul; 30(19):e165-7. PubMed ID: 22665544
[No Abstract] [Full Text] [Related]
9. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
10. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
12. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical oncogenesis: are all BRAF inhibitors equal?
Menzies AM; Kefford RF; Long GV
Pigment Cell Melanoma Res; 2013 Sep; 26(5):611-5. PubMed ID: 23795808
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.
Hecht M; Zimmer L; Loquai C; Weishaupt C; Gutzmer R; Schuster B; Gleisner S; Schulze B; Goldinger SM; Berking C; Forschner A; Clemens P; Grabenbauer G; Müller-Brenne T; Bauch J; Eich HT; Grabbe S; Schadendorf D; Schuler G; Keikavoussi P; Semrau S; Fietkau R; Distel LV; Heinzerling L
Ann Oncol; 2015 Jun; 26(6):1238-1244. PubMed ID: 25762352
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.
Ali M; Anforth R; Senetiner F; Carlos G; Fernandez-Penas P
Exp Dermatol; 2016 May; 25(5):394-5. PubMed ID: 26896751
[No Abstract] [Full Text] [Related]
20. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
